Objective: To examine moderators and predictors of response to behavior therapy for tics in children and adults with Tourette syndrome and chronic tic disorders.
psychiatric disorders, including attentiondeficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), and other anxiety and mood disorders. [3] [4] [5] Available treatments for CTDs focus on tic reduction or a co-occurring condition. Medications to reduce tic severity include dopamine receptor blocking agents (e.g., haloperidol and risperidone) and a2-adrenergic agonists (e.g., clonidine and guanfacine). 6, 7 Efficacy of Comprehensive Behavioral Intervention for Tics (CBIT) 8 for reducing tic severity was demonstrated in 2 large, 10-week randomized controlled trials of youth (n 5 126) 9 and adults (n 5 122). 10 In both trials, CBIT was compared to psychoeducation and supportive therapy (PST).
Given that the CBIT studies used the same design and outcome measures, we combined these datasets to identify baseline characteristics that differentially affected response to CBIT vs PST (moderators) or affected outcome equally across both treatments (predictors).
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METHODS Primary research question. The primary research question was to examine moderators and predictors of response to behavior therapy for tics in children and adults with CTDs. This study provides Class I evidence.
Design. Participants were randomized (1:1) to CBIT or PST.
The random assignment was within-site and stratified by the presence of tic medication.
Participants. Children, adolescents, and adults with diagnosis of TS or CTD with a Clinical Global Impression of Severity (CGI-S) 12 score of moderate (4) or greater were eligible to participate. Those with TS were required to have a Yale Global Tic Severity Scale (YGTSS) 13 Total Tic score of $13 in the child study and $14 in the adult study. For participants with CTD only, the YGTSS total motor or vocal tic scores had to be $9 and $10 in the child and adult studies, respectively. Participants on psychotropic medication (including tic medication) were eligible if the medication was stable for at least 6 weeks before baseline with no planned changes during the 10-week trial. Individuals with IQ ,80, current diagnosis of substance abuse or substance dependence, lifetime diagnosis of autism spectrum disorder or psychotic disorder, or previous treatment with 4 or more sessions of habit reversal training for tics were excluded. Those with co-occurring diagnoses (e.g., depression, anxiety, OCD, or ADHD) were eligible if the condition did not require immediate treatment or change in existing treatment. 9, 10 Three sites enrolled participants in the child study (Johns Hopkins University, University of California at Los Angeles, University of Wisconsin-Milwaukee) and 3 sites enrolled older adolescent and adult participants (Massachusetts General Hospital/Harvard Medical School, Health Sciences Center University of Texas at San Antonio, Yale University). 
Continued
Standard protocol approvals, registrations, and patient consents. The studies were approved by the institutional review boards at each site. Adult participants and parents of child participants provided consent; children provided assent. The child and adult CBIT studies are listed on clinical trials. gov (NCT00218777 and NCT00231985, respectively).
Treatments. CBIT and PST consisted of 8 individually delivered 60-to 90-minute sessions administered over 10 weeks. Caretakers of children and significant others of adults were invited to participate. CBIT provides education about tic disorders and relaxation training and teaches patients to inhibit tics with a competing motor movement. CBIT also addresses situational antecedents and consequences of tics as contextual factors that may inadvertently occasion or reinforce tics. PST provided developmentally relevant information about CTDs and controlled for time and therapist attention, but did not include tic management strategies. Therapists with at least a master's degree were trained to reliability on both treatments and received weekly supervision at each site. Sessions were recorded on video and a 13%-16% randomly selected set of therapy sessions was independently reviewed for fidelity. 9, 10 Procedures. Developmentally appropriate structured diagnostic interviews assessed for psychiatric diagnoses. The Anxiety Disorders Interview Schedule for DSM-IV: Child Version 14 supplemented with a tic disorders module was administered separately to parents and youths in the child study. The Structured Clinical Interview for DSM-IV 15 with tic disorder and adult ADHD modules was used in the adult trial. Symptom severity of ADHD was assessed with parent ratings and self-reports of the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). 16 Outcome measures. The YGTSS 13 is a semi-structured interview that measures tic severity over the prior week. Motor and phonic tics are separately rated on a 0-5 scale for number, frequency, intensity, complexity, and interference. The YGTSS Total Tic score was the first primary outcome measure. The second primary outcome measure was the Clinical Global Impression-Improvement (CGI-I) 12 with scores ranging from very much improved (1) to very much worse (7); scores of much improved (1) or very much improved (2) defined positive response. Trained raters, who were blind to treatment assignment, administered the YGTSS and CGI-I at baseline, midpoint (week 5), and endpoint (week 10).
Moderator and predictor variables. We selected baseline characteristics as moderators that could influence differential response to CBIT vs PST based on studies of behavioral interventions for other neurodevelopmental disorders [19] [20] [21] and on consensus of CBIT investigators. The same variables were examined as predictors, which are characteristics affecting response regardless of treatment assignment. 22 Selected variables included presence of baseline tic medication, tic phenomenology (age at onset, current severity, complexity, and premonitory urges), age, sex, family functioning, treatment expectancy, and co-occurring ADHD, OCD, and anxiety disorders.
Tic medication. Seventy-seven (31%) participants reported taking 1 or more tic medications: 32 antipsychotics, 44 a2 agonists, 5 mood stabilizers, and 4 benzodiazepines. Tic medication status was initially coded 0 (on a medication) or 1 (no tic medication). To test the effects of the most common tic medications in this sample, we created a 4-level variable: 1 5 no tic medications, 2 5 antipsychotics only, 3 5 a2 agonists only, and 4 5 both.
Tic phenomenology. We considered age at onset, tic complexity (cutoff greater than 3 on the YGTSS complexity item), 23 overall severity (CGI-S of moderate vs marked or greater), and premonitory urge based on the 9-item self-report Premonitory Urges for Tics Scale. 24 Demographic and family characteristics. Age was examined as a continuous variable. In addition, we dichotomized age into 9-15 years and $16 years. This division reflects the replicated observation that tics tend to decline throughout adolescence. Thus, study participants age 16 years and older may have a more persistent form of CTDs. Family functioning was measured by the Brief Family Assessment Measure III (BFAM), 25 which reflects family communication, problem-solving, and affective expression. The BFAM was completed by caregivers and participants in the child study and by adult participants. A z score was created based on the average of child and parent BFAM scores and the raw scores from adult participants.
Treatment expectations. After the first CBIT or PST session, we collected a 3-item questionnaire from participants, parents, and therapists in the child study and from participants and therapists in the adult study. Items such as "I expect to get control over my tics though this treatment" were rated on a scale from 1 5 strongly disagree to 5 5 strongly agree. Thus, higher scores indicated greater expectancy for treatment benefits. z Scores were derived from the average of child and parent ratings in the child study and self-reports in the adult study and then merged. We also created a z score for therapist treatment expectation across both trials.
Data analysis. The effect of treatment on the YGTSS Total
Tic score was tested with mixed-model repeated-measures analyses, adjusted for baseline scores. 26 These analyses were conducted on the modified intention-to-treat population (all participants with at least 1 postrandomization assessment visit [n 5 232]). The model included fixed effects for treatment (2 levels), time (5 and 10 weeks), site (6 sites), interaction of treatment with time, a random effect for participant, and 3-and 2-way interactions of time, treatment, and moderator variable. Treatment-by-site interactions were not significant for any of the outcome variables and were excluded from the models. Three-way interactions (treatment 3 time 3 moderator) were not significant and were dropped from all models. In the absence of any significant 3-way interactions, we examined 2-way interactions (moderator 3 treatment) on the assumption that treatment differences between levels of the moderator were the same at weeks 5 and 10. To identify predictors of change on the YGTSS Total Tic score, we checked for significant main effects for baseline characteristics regardless of treatment assignment. 22 Given the exploratory nature of these moderator and predictor analyses, we did not correct for multiple comparisons. 26 Dichotomously coded moderator variables were entered in the mixed model repeated-measures analysis with adjustment for baseline YGTSS scores. Continuous variables were centered prior to analysis by subtracting the variable mean from the individual scores. Baseline and endpoint adjusted least squares means and SD for the YGTSS Total Tic score for the CBIT and PST groups stratified by the moderator variables are presented. Effect sizes were calculated by subtracting the change in YGTSS scores in PST from the change in the CBIT divided by the SD for the full sample at baseline. (table 1) . Additional characteristics of the child and adult participants have been reported elsewhere. 9, 10, 23, 27 Moderation. The presence of tic medication significantly moderated response to CBIT, favoring those on no tic medication (F 1 (table 2) . Table 3 shows least squares means (LSM) and SD for participants receiving and not receiving medication by the treatment condition. Using LSM, the treatment comparison at week 10 in the CBIT condition for participants receiving vs not receiving medication was statistically significant (t 5 2.09, p 5 0.04). For participants on a2 agonists, the comparison of week 10 LSM revealed no difference between CBIT and PST (t 5 0.82, p 5 0.41). In contrast, participants in the PST condition who were receiving a2 agonists showed significantly greater tic reduction that participants not on tic medication (t 5 22.37, p 5 0.019). The presence of ADHD did not moderate treatment effect in participants ,18 years old (n 5 152) (F 1,132 5 0.01, p 5 0.94) or in the combined child and adult samples (n 5 248, F 1,222 5 0.13, p 5 0.72). Moderating effects of ADHD symptom severity tested using ADHD-RS z scores were not significant in children and adults separately or in the combined sample ( There were no significant treatment interactions with age at onset, presence of complex tics, tic severity on the CGI-S, the severity of premonitory urges, sex, BFAM, participant, or therapist expectancy (table 2) . Baseline age (centered variable), as a continuous variable or when dichotomized into younger and older age groups, did not moderate outcome.
RESULTS
The effect size for CBIT vs PST was 1.02 for participants not on tic medication compared to 0.27 for those on tic medication. To evaluate further the moderating effects of tic medication, we compared participants on no tic medication, antipsychotics only, a2 agonists only, or both (table 3  and figure) . Participants on a2 agonists (CBIT n 5 17; PST n 5 20) showed similar improvement in both groups (t 5 0.82, p 5 0.41; effect size 5 0.07). By contrast, for participants on antipsychotic medication (CBIT n 5 14; PST n 5 11), the treatment difference was only slightly lower than the treatment difference for participants not on tic medication (t 5 1.39, p 5 0.16; effect size 5 0.77). Table 4 shows the overall rate of positive response on the CGI-I and by tic medication status. For participants on no tic medication, the rate of positive response in CBIT was significantly greater than for PST. For participants on a tic medication, the response rate for CBIT was twice that for PST, but this difference was not significant.
Predictors. There were no significant main effects on age at onset, presence of complex tics, sex, or family functioning. Greater overall severity at baseline as measured on the CGI-S predicted a greater reduction of tics regardless of treatment condition (F 1,222 5 8.22, p 5 0.005). Greater severity of premonitory urges at baseline predicted lesser tic reduction in both treatments (F 1,225 5 8.13, p 5 0.005). Positive expectancy by participants was Table 3 Least squares means (SD) Yale Global Tic Severity Scale Total Tic scores by treatment group stratified by tic medication, presence of ADHD, OCD, and anxiety disorders, and by moderate vs severe tics DISCUSSION Data from the child and adult CBIT vs PST trials (n 5 248) were combined to examine moderators and predictors of treatment response. Compared to participants on tic medication, the treatment effect of CBIT was significantly larger in participants on no tic medication. This differential response was evident in the YGTSS Total Tic score and the rate of positive response on the CGI-I scored by a blinded evaluator. The presence of a lifetime diagnosis of ADHD, OCD, or other anxiety disorders did not moderate treatment response to CBIT, nor did age, sex, current severity of ADHD symptoms, tic severity, or severity of premonitory urges.
The moderating effect of tic-suppressing medication warrants closer inspection. First, the use of tic-suppressing medication may indicate greater tic severity. At baseline, there was no difference in YGTSS Total Tic scores in participants on tic medication compared to those not taking a tic medication. However, because the premedication tic severity for those on tic medication is unknown, the role of tic severity in these analyses is unclear.
Second, of the 248 participants, only 77 (31%) were on a tic-suppressing medication (primarily antipsychotics or a2 agonists). As shown in table 3, the difference in YGTSS change scores between CBIT and PST was 1.7 points for participants on any tic medication compared to a difference of 6.4 points for participants not on tic medication (effect sizes 0.27 and 1.02, respectively). Although the numbers are small, there were differences by drug class. The CBIT-PST YGTSS change-score difference for participants on antipsychotic medications was 4.9 points (effect size 0.77), which was similar to the improvement in participants on no tic medication. By contrast, for participants on a2 agonists, the difference in YGTSS change scores between treatments was 0.4 points (effect size 0.07). This attenuated effect size was largely due to the 6.1-point improvement in the YGTSS in the PST group on a2 agonists compared to a 6.5-point reduction in CBIT. When examined categorically on the CGI-I, participants on no tic medication showed a higher positive response rate than those on tic medication with no apparent difference by drug class.
Although participants not on tic medication showed greater magnitude of benefit and likelihood of positive response, participants on tic medication also showed improvement with CBIT. Thus, within the CBIT group, there was a 7.3-point reduction in the YGTSS Total Tic score in participants not on tic-suppressing medication. This is remarkably similar to the 6.5-point reduction for CBIT in participants receiving a2 agonists for tics and the 8.5-point reduction in participants on antipsychotics for tics. The 6.1-point decrease in tic severity in the PST group on a2 agonists for tics reduced the treatment difference between CBIT and PST for all participants on tic medication and may explain the significant interaction. The smaller CBIT-PST treatment difference in participants on a2 agonists need not imply that patients on a2 agonists should not be offered CBIT.
The predictor analysis identified 4 variables that affected outcome regardless of treatment assignment: co-occurring anxiety disorders, severity of premonitory urges, participant positive expectancy, and higher overall severity as measured on the CGI-S. Participants with a co-occurring anxiety disorder showed less tic reduction after 10 weeks. Although CBIT includes brief relaxation training, incorporation of more active anxiety and stress management strategies in CBIT may be useful. The severity of premonitory urges was also associated with lower tic reduction. Despite the deliberate teaching on early detection of the urge and initiation of voluntary competing response in CBIT, premonitory urges did not improve with CBIT. 9, 10 The current analysis suggests that the severity of premonitory urges impeded improvement in both study treatments. Greater levels of premonitory urges may be associated with more treatment-resistant forms of CTDs. 28 Positive expectancy for change among study participants and parents was associated with greater tic reduction over time. This nonspecific effect suggests that some participants and their parents were optimistic that therapeutic attention to the problem of chronic tics could be beneficial. 29 When overall severity was dichotomized on CGI-S of moderate vs marked or greater, participants with greater overall severity also showed greater tic reduction over time regardless of treatment condition.
Positive expectations for treatment depend, at least in part, on agreement between the patient and the clinician on the goals of treatment as well as the specific components of the therapy. 30 Thus, open discussion about the goal (tic reduction) and techniques of CBIT (e.g., awareness training and competing response training) between the therapist and the patient is warranted.
These results should be considered in light of limitations. First, the CBIT studies were designed to test main effects. By definition, moderator and predictor analyses are exploratory. Second, although the effect size and likelihood of positive response were lower for participants on tic medication, the subgroups by medication class were small, making it difficult to interpret the findings.
CBIT is helpful for reducing tics in children and adults regardless of coexisting tic medication treatment, although the difference between CBIT and PST was smaller for participants on tic-suppressing medications. PST was designed to include psychoeducation and support that are part of good clinical practice and it should be provided to patients in conjunction with medication management for tics. The presence of common co-occurring conditions in children and adults with CTDs did not moderate treatment effects, suggesting that CBIT is effective for reducing tic severity in patients with stable cooccurring conditions.
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